Pancreatic Cancer Research

ResearcherUinta Bio, Inc.Active in the last 2 years

Masato Yamamoto

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-2721-6245; OpenAlex author ID A5040557156; NIH RePORTER profile ID 7066184. Sources: OpenAlex.

Their work

Papers
16 (first author 1, last author 7)
Trials
0
Grants
7
Labs led
1
Collaborators
32
Papers, trials and grants by year

2012: 2 papers · 2013: 2 papers, 1 grant · 2014: 1 paper · 2015: 2 papers · 2016: none · 2017: 1 grant · 2018: 3 papers · 2019: none · 2020: 1 grant · 2021: none · 2022: 2 papers · 2023: 1 paper, 1 grant · 2024: none · 2025: 1 paper · 2026: 2 papers, 3 grants

Papers 16

  1. High intrapancreatic fat deposition accelerates pancreatic ductal adenocarcinoma growth and metastasis with enrollment of FABP5 upregulation. Co-author DOI 10.1038/s41598-026-56838-2↗
  2. Targeting pancreatic cancer with adenoviral vectors equipped with transgenes. Last author DOI 10.1158/1535-7163.mct-25-1231↗
  3. Inhibition of fatty acid binding protein suppresses pancreatic cancer progression and metastasis. Last author DOI 10.1038/s41598-025-11271-9↗
  4. Interferon-expressing oncolytic adenovirus + chemoradiation inhibited pancreatic cancer growth in a hamster model. Last author DOI 10.1111/cas.15903↗
  5. Fatty acid binding protein 4 regulates pancreatic cancer cell proliferation via activation of nuclear factor E2-related factor 2. Last author DOI 10.1016/j.soard.2021.12.002↗
  6. Obesity and Pancreatic Cancer: Recent Progress in Epidemiology, Mechanisms and Bariatric Surgery. Last author DOI 10.3390/biomedicines10061284↗
  7. Combination of interferon-expressing oncolytic adenovirus with chemotherapy and radiation is highly synergistic in hamster model of pancreatic cancer. Co-author DOI 10.18632/oncotarget.24710↗
  8. The Development of Oncolytic Adenovirus Therapy in the Past and Future - For the Case of Pancreatic Cancer First author DOI 10.2174/1568009617666170222123925↗
  9. Role of Gene Therapy in Pancreatic Cancer-A Review. Last author DOI 10.3390/cancers10040103↗
  10. Oncolytic adenovirus expressing interferon alpha in a syngeneic Syrian hamster model for the treatment of pancreatic cancer. Co-author DOI 10.1016/j.surg.2015.01.006↗
  11. CD133 initiates tumors, induces epithelial-mesenchymal transition and increases metastasis in pancreatic cancer. Co-author DOI 10.18632/oncotarget.3228↗
  12. Triptolide activates unfolded protein response leading to chronic ER stress in pancreatic cancer cells. Co-author DOI 10.1152/ajpgi.00466.2013↗
  13. Intravenous genetic mesothelin vaccine based on human adenovirus 40 inhibits growth and metastasis of pancreatic cancer. Last author DOI 10.1002/ijc.27983↗
  14. Conditionally replicative adenoviral vectors for imaging the effect of chemotherapy on pancreatic cancer cells. Co-author DOI 10.1111/cas.12196↗
  15. Generation of a novel, cyclooxygenase-2-targeted, interferon-expressing, conditionally replicative adenovirus for pancreatic cancer therapy. Co-author DOI 10.1016/j.amjsurg.2012.02.016↗
  16. Delivery of interferon alpha using a novel Cox2-controlled adenovirus for pancreatic cancer therapy. Co-author DOI 10.1016/j.surg.2012.02.017↗

Grants 7

  1. Advanced Oncolytic Adenovirus Enabling Systemic Therapy of PDAC R01CA276480↗
  2. Novel combination immunotherapy with oncolytic adenovirus and immune checkpoint inhibitors for pancreatic ductal adenocarcinoma. R41CA314730↗
  3. Training the Next Generation of Surgeon-Scientists in Pancreatology T32DK108733↗
  4. Combination therapy with IFN expressing oncolytic adenovirus for pancreatic cancer R01CA228760↗
  5. Systemic Therapy with Infectivity-Selective Oncolytic Adenovirus for PDAC R01CA196215↗
  6. Next Generation Oncolytic Adenovirus for Advanced Pancreatic Cancer Treatment R01CA168448↗
  7. Enhanced CRAd for Pancreatic Cancer R01CA094084↗

Closest collaborators

The 25 strongest of 32 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Mizuho Sato‐Dahlman · 6 shared papers, 2018–2026 · strength 1.27
  2. Charlotte Anne Casebourne Stock · 1 shared grant, 2026 · strength 1.26
  3. Julia Davydova · 6 shared papers, 1 shared grant, 2012–2023 · strength 1.23
  4. Shuhei Shinoda · 5 shared papers, 2022–2026 · strength 1.10
  5. Gregory J Beilman · 1 shared grant, 2026 · strength 1.00
  6. Srinath Chinnakotla · 1 shared grant, 2026 · strength 1.00
  7. Brett Roach · 2 shared papers, 2022–2026 · strength 0.52
  8. Kazuho Inoko · 2 shared papers, 2023–2025 · strength 0.45
  9. Ingunn M. Stromnes · 1 shared paper, 2026 · strength 0.33
  10. Keith M. Wirth · 2 shared papers, 2018–2022 · strength 0.31
  11. Kaori Hamamoto · 1 shared paper, 2026 · strength 0.29
  12. Shin Hamada · 1 shared paper, 2026 · strength 0.29
  13. Taro Takami · 1 shared paper, 2026 · strength 0.29
  14. Shigeyuki Suenaga · 1 shared paper, 2026 · strength 0.29
  15. Atsushi Masamune · 1 shared paper, 2026 · strength 0.29
  16. Selwyn Maurice Vickers · 6 shared papers, 2012–2015 · strength 0.26
  17. Nikita Sharma · 1 shared paper, 2023 · strength 0.19
  18. Christopher James LaRocca · 2 shared papers, 2015–2018 · strength 0.15
  19. Leonard Armstrong · 3 shared papers, 2012–2015 · strength 0.12
  20. Sulagna Banerjee · 2 shared papers, 2014–2015 · strength 0.10
  21. Rohit Chugh · 2 shared papers, 2014–2015 · strength 0.10
  22. Ashok Kumar Saluja · 2 shared papers, 2014–2015 · strength 0.10
  23. Vikas Dudeja · 2 shared papers, 2014–2015 · strength 0.10
  24. Amanda O. Salzwedel · 1 shared paper, 2018 · strength 0.10
  25. Alice Nomura · 1 shared paper, 2015 · strength 0.06

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.